STLN · Starling Oncology Inc
United States · RS rating 94 · As of 2026-11-03
| Price | 6.34 USD |
|---|---|
| 1-day change | +1.4% |
| RS rating (overall / 1M / 3M / 12M) | 94 / 59 / 91 / 81 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 45 / 66 / 46 |
| Industry group (rank) | Medical-Hospitals (27) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +9.4% |
| Distance from 52-week high | +10.1% |
| Market cap (USD) | $640.9M |